P Arora1,2, Z Agarwal3, A Venkatraman4, P Callas5, B M Kissela6, N S Jenny7, S E Judd8, N A Zakai3,7, M Cushman3,7. 1. Division of Cardiology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. 3. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. 4. Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA. 6. Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, USA. 7. Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. 8. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract
BACKGROUND AND PURPOSE: Galectin-3 is a biomarker of atherosclerotic and cardiovascular disease, and may be a useful marker for ischaemic stroke risk. METHODS: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort enrolled and examined 30 239 US participants between 2003 and 2007 (41% black, 59% white and 55% in the southeastern stroke belt). Baseline galectin-3 was measured in 526 subjects with incident ischaemic stroke over 5.4 years and in a cohort random sample (CRS) of 947 participants. Cox proportional hazards models were used to calculate hazard ratios (HRs) of ischaemic stroke by quartiles of galectin-3. RESULTS: In the CRS, galectin-3 was significantly higher with older age, black race, female sex, body mass index, hypertension, diabetes mellitus and kidney disease, and also in those who developed incident stroke. Participants with galectin-3 levels in the fourth versus first quartile had a 2.3-fold increased stroke risk [95% confidence interval (CI) 1.6, 3.4] in an unadjusted model. An interaction with age was found (P = 0.06), and therefore age-stratified analyses were performed. Amongst those younger than age 64, baseline galectin-3 in the second-fourth quartiles was associated with increased stroke risk (HR 3.0, 95% CI 1.6, 5.5) compared to the first quartile in an age-, race- and sex-adjusted model. The HR was 2.0 (95% CI 1.0, 4.0) with multivariable adjustment. There was no association amongst older participants. CONCLUSIONS: Galectin-3 was associated with incident ischaemic stroke in younger but not older individuals. Confirmation of this finding, and elucidation of its implications for stroke pathophysiology and prevention, is needed.
BACKGROUND AND PURPOSE: Galectin-3 is a biomarker of atherosclerotic and cardiovascular disease, and may be a useful marker for ischaemic stroke risk. METHODS: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort enrolled and examined 30 239 US participants between 2003 and 2007 (41% black, 59% white and 55% in the southeastern stroke belt). Baseline galectin-3 was measured in 526 subjects with incident ischaemic stroke over 5.4 years and in a cohort random sample (CRS) of 947 participants. Cox proportional hazards models were used to calculate hazard ratios (HRs) of ischaemic stroke by quartiles of galectin-3. RESULTS: In the CRS, galectin-3 was significantly higher with older age, black race, female sex, body mass index, hypertension, diabetes mellitus and kidney disease, and also in those who developed incident stroke. Participants with galectin-3 levels in the fourth versus first quartile had a 2.3-fold increased stroke risk [95% confidence interval (CI) 1.6, 3.4] in an unadjusted model. An interaction with age was found (P = 0.06), and therefore age-stratified analyses were performed. Amongst those younger than age 64, baseline galectin-3 in the second-fourth quartiles was associated with increased stroke risk (HR 3.0, 95% CI 1.6, 5.5) compared to the first quartile in an age-, race- and sex-adjusted model. The HR was 2.0 (95% CI 1.0, 4.0) with multivariable adjustment. There was no association amongst older participants. CONCLUSIONS: Galectin-3 was associated with incident ischaemic stroke in younger but not older individuals. Confirmation of this finding, and elucidation of its implications for stroke pathophysiology and prevention, is needed.
Authors: George Howard; Brett M Kissela; Dawn O Kleindorfer; Leslie A McClure; Elsayed Z Soliman; Suzanne E Judd; J David Rhodes; Mary Cushman; Claudia S Moy; Kara A Sands; Virginia J Howard Journal: Neurology Date: 2016-01-20 Impact factor: 9.910
Authors: Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai Journal: Stroke Date: 2014-04-22 Impact factor: 7.914
Authors: Miguel Angel Burguillos; Martina Svensson; Tim Schulte; Antonio Boza-Serrano; Albert Garcia-Quintanilla; Edel Kavanagh; Martiniano Santiago; Nikenza Viceconte; Maria Jose Oliva-Martin; Ahmed Mohamed Osman; Emma Salomonsson; Lahouari Amar; Annette Persson; Klas Blomgren; Adnane Achour; Elisabet Englund; Hakon Leffler; Jose Luis Venero; Bertrand Joseph; Tomas Deierborg Journal: Cell Rep Date: 2015-03-05 Impact factor: 9.423
Authors: R A de Boer; D J van Veldhuisen; R T Gansevoort; A C Muller Kobold; W H van Gilst; H L Hillege; S J L Bakker; P van der Harst Journal: J Intern Med Date: 2011-11-18 Impact factor: 8.989
Authors: Lars Gullestad; Thor Ueland; John Kjekshus; Ståle H Nymo; Johannes Hulthe; Pieter Muntendam; John J V McMurray; John Wikstrand; Pål Aukrust Journal: Am Heart J Date: 2012-10-29 Impact factor: 4.749
Authors: Samuel Ap Short; Katherine Wilkinson; D Leann Long; Suzanne Judd; Janin Schulte; Brett M Kissela; George Howard; Mary Cushman Journal: J Stroke Cerebrovasc Dis Date: 2021-12-09 Impact factor: 2.136